PVLA — PALVELLA THERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1583648 ·
Last close
$144.76
Market Cap
$2.08B
52W High
$161.38
52W Low
$100.00
ADV30
310,222
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -14,855,000 | -15,767,000 | 263,759,000 | 206,394,000 | 31,446,000 |
| Dec 2025 | 0 | — | -11,304,000 | -12,714,000 | 59,559,000 | 57,982,000 | 31,576,000 |
| Sep 2025 | 0 | — | -10,177,000 | -11,345,000 | 66,937,000 | 63,567,000 | 28,255,000 |
| Jun 2025 | 0 | — | -9,250,000 | -9,471,000 | 73,747,000 | 70,433,000 | 25,967,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-25,006,000
Investing CF
—
Financing CF
$-660,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.25
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-135,450,000
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-35,897,000
Pretax Income TTM
$-41,715,000
Interest Exp TTM
$5,818,000
Analysts
15
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -38,602,000 | -41,715,000 | 59,559,000 | 31,576,000 | — | -25,006,000 |
| Dec 2024 | 0 | -14,095,000 | -17,434,000 | 88,234,000 | 25,627,000 | — | -10,840,000 |
| Dec 2023 | 0 | -11,869,000 | 18,691,000 | 7,548,000 | 11,428,000 | — | -13,703,000 |
| Dec 2022 | 0 | -18,040,000 | -27,552,000 | 16,524,000 | 39,698,000 | — | -14,840,000 |
TTM Snapshot
Revenues TTM
$29,701,000
NetIncome TTM
$-38,526,000
OpCashFlow TTM
$0
Assets (Latest)
$153,560,000
Forward EPS
$-6.82
Max Pain — expiry 2026-07-17
max pain strike: $100.00 · spot: $144.76 · call oi: 1,582 · put oi: 2,098
Expected Move to 2026-07-17:
±$9.40
(6.49%) —
implied range
$135.36 –
$154.16
· ATM straddle on $145.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ABCL | AbCellera Biologics Inc. | $2.08B | $6.80 | — |
| SNDX | Syndax Pharmaceuticals Inc | $2.09B | $23.61 | — |
| SION | Sionna Therapeutics, Inc. | $2.04B | $45.29 | — |
| NBTX | Nanobiotix S.A. | $2.03B | $40.07 | — |
| AUPH | Aurinia Pharmaceuticals Inc. | $2.03B | $15.78 | — |
News headlines (Yahoo Finance, 1h cache)
Palvella Therapeutics Appoints Accomplished Rare Disease Biotech Executive and Commercial Leader Matt Pauls, J.D., M.B.A., to Board of Directors
2026-06-30 11:30 · Yahoo
Palvella Therapeutics Submits First Module of Rolling New Drug Application to FDA for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
2026-06-29 11:30 · Yahoo
What to Know About This $476,000 Palvella Therapeutics Insider Sale After a 620% Stock Rally
2026-06-27 16:31 · Yahoo
Palvella Shares Advance After FDA Grants Rolling Review for Rare Disease Therapy
2026-06-22 12:49 · Yahoo
FDA Grants Rolling Review of Palvella’s QTORIN™ Rapamycin NDA for Microcystic Lymphatic Malformations
2026-06-22 11:30 · Yahoo
Palvella Therapeutics (PVLA) Stock Valuation Check After Strong Recent Momentum
2026-06-16 00:16 · Yahoo
Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations
2026-06-03 11:30 · Yahoo
Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
2026-06-02 11:30 · Yahoo
Palvella Therapeutics Strengthens QTORIN™ Pitavastatin Intellectual Property with Yale-Licensed U.S. Patent Providing Protection into 2043
2026-05-27 11:30 · Yahoo
Palvella Therapeutics Named Healthcare & Life Sciences Company of the Year at the Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards
2026-05-21 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.